Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 3/2023

27-02-2023 | ST-Segment Elevation Myocardial Infarction | Editorial

When Is It Appropriate to Publish a Meta-Analysis in Cardiovascular Drugs and Therapy?

Authors: Charles Maynard, Salim Virani, Hani Jneid, Yochai Birnbaum

Published in: Cardiovascular Drugs and Therapy | Issue 3/2023

Login to get access

Excerpt

The method of meta-analysis has been in existence for hundreds of years in various scientific disciplines, but it was only in the twentieth century that clinical scientists began to address medical questions by combining results from different randomized clinical trials and observational studies [1]. The method of summarizing results from different studies has become the formalized method known as meta-analysis, which has been defined as “a statistical analysis of results from separate studies, examining sources of differences in results among studies, and leading to a quantitative summary of the results if the results are judged sufficiently similar or consistent to support such synthesis [2].” This is especially important when the sample size for individual studies is small leading to uncertainty about the effect size and wide confidence intervals pertaining to the treatment. The statistical methods for conducting meta-analyses have evolved over time and continue to do so. …
Literature
2.
go back to reference Porta M. A Dictionary of Epidemiology. 6th ed. Oxford: Oxford University Press; 2016. p. 320. Porta M. A Dictionary of Epidemiology. 6th ed. Oxford: Oxford University Press; 2016. p. 320.
3.
go back to reference Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311–22.CrossRef Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311–22.CrossRef
4.
go back to reference Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:P955–62.CrossRef Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:P955–62.CrossRef
5.
go back to reference Sardar P, Chatterjee S, Wu WC, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One. 2013;8: e77694.CrossRefPubMedPubMedCentral Sardar P, Chatterjee S, Wu WC, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One. 2013;8: e77694.CrossRefPubMedPubMedCentral
6.
go back to reference Kitsios GD, Thaler DE, Kent DM. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke. 2013;44:2640–3.CrossRefPubMed Kitsios GD, Thaler DE, Kent DM. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke. 2013;44:2640–3.CrossRefPubMed
7.
go back to reference Kolokathis K, Thomopoulos C, Tsioufis K. Net clinical benefit of PFO closure versus medical treatment in patients with cryptogenic stroke: A systematic review and meta-analysis. Hellenic J Cardiol. 2022, in press. Kolokathis K, Thomopoulos C, Tsioufis K. Net clinical benefit of PFO closure versus medical treatment in patients with cryptogenic stroke: A systematic review and meta-analysis. Hellenic J Cardiol. 2022, in press.
8.
go back to reference Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.​training.​cochrane.​org/​handbook.
9.
go back to reference Borenstine M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis, John Wiley and Sons, Ltd, 2009,364. Borenstine M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis, John Wiley and Sons, Ltd, 2009,364.
10.
go back to reference Berlin JA, Rubenfeld GD, O’Cearbhaill RE, Sanghavi S, Fihn SD. Keeping meta-analyses fresh. JAMA Network Open. 2022;5(8): e2228541.CrossRefPubMed Berlin JA, Rubenfeld GD, O’Cearbhaill RE, Sanghavi S, Fihn SD. Keeping meta-analyses fresh. JAMA Network Open. 2022;5(8): e2228541.CrossRefPubMed
11.
go back to reference Zanad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis, of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–29.CrossRef Zanad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis, of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–29.CrossRef
Metadata
Title
When Is It Appropriate to Publish a Meta-Analysis in Cardiovascular Drugs and Therapy?
Authors
Charles Maynard
Salim Virani
Hani Jneid
Yochai Birnbaum
Publication date
27-02-2023
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2023
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-023-07445-0

Other articles of this Issue 3/2023

Cardiovascular Drugs and Therapy 3/2023 Go to the issue